INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

被引：13

作者：

Colombo, N. ^{[1
,2
]}

Gadducci, A. ^{[3
]}

Sehouli, J. ^{[4
]}

Rulli, E. ^{[5
]}

Maenpaa, J. ^{[6
,7
,8
,9
]}

Sessa, C. ^{[10
,11
]}

Montes, A. ^{[12
]}

Ottevanger, N. B. ^{[13
]}

Berger, R. ^{[14
,15
]}

Vergote, I. ^{[16
,17
]}

D'Incalci, M. ^{[5
,18
]}

Galaz, C. Churruca ^{[19
,20
]}

Chekerov, R. ^{[4
]}

Nyvang, G. B. ^{[21
,22
]}

Riniker, S. ^{[23
,24
]}

Herbertson, R. ^{[25
]}

Fossati, R. ^{[5
]}

Barretina-Ginesta, M. P. ^{[26
,27
]}

Deryal, M. ^{[28
,29
]}

Mirza, M. R. ^{[30
,31
]}

Biagioli, E. ^{[5
]}

Iglesias, M. ^{[32
,33
]}

Funari, G. ^{[5
]}

Romeo, M. ^{[34
,35
]}

Tasca, G. ^{[36
,37
]}

Pardo, B. ^{[38
]}

Tognon, G. ^{[39
,40
]}

Rubio-Perez, M. J. ^{[41
]}

DeCensi, A. ^{[42
]}

De Giorgi, U. ^{[43
]}

Zola, P. ^{[44
]}

Panici, P. Benedetti ^{[45
,46
]}

Aglietta, M. ^{[47
]}

Arcangeli, V. ^{[48
]}

Zamagni, C. ^{[49
]}

Bologna, A. ^{[50
]}

Westermann, A. ^{[51
]}

Heinzelmann-Schwarz, V. ^{[52
,53
]}

Tsibulak, I. ^{[14
,15
]}

Wimberger, P. ^{[54
,55
,56
,57
,58
]}

Poveda, A. ^{[59
,60
]}

机构：

[1] IRCCS, European Inst Oncol, Gynecol Canc Program, Milan, Italy

[2] Univ Milano Bicocca, Milan, Italy

[3] Univ Pisa, Div Obstet & Gynecol, Clin & Expt Med, Pisa, Italy

[4] Charite Berlin Univ Med, European Competence Ctr Ovarian Canc, North Eastern German Soc Gynecol Oncol NOGGO, Study Grp & Gynecol,Ctr Oncol Surg, Berlin, Germany

[5] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy

[6] Tampere Univ, Nord Soc Gynecol Oncol Clin Trial Unit NSGOCTU, Tampere, Finland

[7] Tampere Univ, Dept Obstet & Gynaecol, Tampere, Finland

[8] Tampere Univ, Tays Canc Ctr, Tampere, Finland

[9] Univ Hosp, Tampere, Finland

[10] Ist Oncol Svizzera Italiana, IOSI, Bellinzona, Switzerland

[11] Swiss Grp Clin Canc Res SAKK, Bellinzona, Switzerland

[12] Guys & St Thomas NHS Fdn Trust, London, England

[13] Radboud Univ Nijmegen, Med Ctr, Med Oncol, Nijmegen, Netherlands

[14] Med Univ Innsbruck, Dept Gynecol & Obstet, Innsbruck, Austria

[15] AGO, Innsbruck, Austria

[16] Univ Hosp Leuven, Leuven Canc Inst, Gynecol Oncol, Leuven, Belgium

[17] European Union, Belgian Gynaecol Oncol Grp BGOG, Leuven, Belgium

[18] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy

[19] Hosp Donosti San Sebastian, De Donosti San, Spain

[20] Grp Espanol Canc Ovario GEICO, De Donosti San, Spain

[21] Odense Univ Hosp, Nord Soc Gynecol Oncol Clin Trial Unit NSGO CTU, Odense, Denmark

[22] Odense Univ Hosp, Dept Oncol, Odense, Denmark

[23] Kantonsspital St Gallen, Oncol, St Gallen, Switzerland

[24] Swiss Grp Clin Canc Res SAKK, St Gallen, Switzerland

[25] Brighton & Sussex Univ Hosp NHS Trust, Brighton, E Sussex, England

[26] Inst Catala Oncologia Girona, De Donosti San, Spain

[27] Girona & Grp Espanol Canc Ovario GEICO, De Donosti San, Spain

[28] North Eastern German Soc Gynecol Oncol NOGGO, Study Grp, Saarbrucken, Germany

[29] CaritasKlinikum St Theresia Saarbruecken, Saarbrucken, Germany

[30] Copenhagen Univ Hosp, Nord Soc Gynecol Oncol Clin Trial Unit NSGO CTU, Copenhagen, Denmark

[31] Copenhagen Univ Hosp, Dept Canc Treatment, Copenhagen, Denmark

[32] Hosp Son Llazter, Palma De Mallorca, Spain

[33] Grupo Espanol Canc Ovario GEICO, Palma De Mallorca, Spain

[34] Inst Catala Oncologia Badalona, De Donosti San, Spain

[35] Grp Espanol Canc Ovario GEICO, De Donosti San, Spain

[36] Inst Catala Oncol Hosp, Barcelona, Spain

[37] Grp Espanol Canc Ovario GEICO, Barcelona, Spain

[38] ASST Spedali Civili Univ Brescia, Obstetr & Gynaecol, Brescia, Italy

[39] Hosp Reina Sofia Cordoba, De Donosti San, Spain

[40] Grp Espanol Canc Ovario GEICO, De Donosti San, Spain

[41] EO Ospedali Galliera, SC Oncol Med, Genoa, Italy

[42] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Meldola, Italy

[43] AOU Citta Salute & Scienza OIRM S Anna, Turin, Italy

[44] AOU Policlin I Umberto Roma, Rome, Italy

[45] Univ Torino, Ist Candiolo, FPO IRCCS, Turin, Italy

[46] Univ Torino, Turin, Italy

[47] Ospedale Infermi, Rimini, Italy

[48] Univ Bologna, IRCCS Azienda Ospedaliero, Bologna, Italy

[49] IRCCS, Azienda Unita Sanit Locale Reggio Emilia, Reggio Emilia, Italy

[50] Amsterdam UMC, Amsterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2023年 / 128卷 / 08期

关键词：

QUALITY-OF-LIFE; OPEN-LABEL; TRIAL; EFFICACY; MULTICENTER; SAFETY; SENSITIVITY; COMBINATION; EVALUATE; THERAPY;

D O I：

10.1038/s41416-022-02108-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). METHODS: Patients with OC (up to two previous platinum-based lines), with a TFIp of 6-12 months, were randomised to receive carboplatin/PLD (CP) or TP followed by platinum therapy at relapse. The primary endpoint was OS (HR: 0.75). RESULTS: The study enrolled 617 patients. The median TFIp was 8.3 months and 30.3% of patients had received two previous platinum lines. 74% and 73.9% of patients, respectively, received a subsequent therapy (ST) in the CP and TP arm; in the latter TP arm 87.2% of ST was platinum-based, as per protocol. The median OS was 21.4 for CP and 21.9 months for TP (HR 1.13; 95% CI: 0.94-1.35; p = 0.197). Grade 3-5 adverse reactions occurred in 37.1% of patients in the CP arm and 69.7% of patients in the TP arm, and the most frequent were neutropenia (22.8% CP, 39.5% TP), gastrointestinal (7.1% CP, 17.4% TP), hepatic (0.7% CP, 19.1% TP). CONCLUSIONS: This study did not meet the primary endpoint. CP combination remains the standard for patients with recurrent OC and a 6-12 months TFIp; TP is an effective treatment in patients suffering from persistent platinum toxicities.

引用

页码：1503 / 1513

页数：11

共 25 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
AARONSON, NK
AHMEDZAI, S
BERGMAN, B
BULLINGER, M
CULL, A
DUEZ, NJ
FILIBERTI, A
FLECHTNER, H
FLEISHMAN, SB
DEHAES, JCJM
KAASA, S
KLEE, M
OSOBA, D
RAZAVI, D
ROFE, PB
SCHRAUB, S
SNEEUW, K
SULLIVAN, M
TAKEDA, F
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
[2] Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
Colmegna, B.
Uboldi, S.
Frapolli, R.
Licandro, S. A.
Panini, N.
Galmarini, C. M.
Badri, Nadia
Spanswick, V. J.
Bingham, J. P.
Kiakos, Konstantinos
Erba, E.
Hartley, J. A.
D'Incalci, M.
[J]. BRITISH JOURNAL OF CANCER, 2015, 113 (12) : 1687 - 1693
[3] Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
Colombo, Nicoletta
Zaccarelli, Eleonora
Baldoni, Alessandra
Frezzini, Simona
Scambia, Giovanni
Palluzzi, Eleonora
Tognon, Germana
Lissoni, Andrea A.
Rubino, Daniela
Ferrero, Annamaria
Farina, Gabriella
Negri, Emanuele
Gritti, Angela Pesenti
Galli, Francesca
Biagioli, Elena
Rulli, Eliana
Poli, Davide
Gerardi, Chiara
Torri, Valter
Fossati, Roldano
D'Incalci, Maurizio
[J]. BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 744 - 750
[4] Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
Damia, G
Silvestri, S
Carrassa, L
Filiberti, L
Faircloth, GT
Liberi, G
Foiani, M
D'Incalci, M
[J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (04) : 583 - 588
[5] Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
Erba, E
Bergamaschi, D
Bassano, L
Damia, G
Ronzoni, S
Faircloth, GT
D'Incalci, M
[J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (01) : 97 - 105
[6] Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO 2/ENGOT Ov-21 trial
Frenel, J-S.
Kim, J-W.
Berton-Rigaud, D.
Asher, R.
Vidal, L.
Pautier, P.
Ledermann, J. A.
Penson, R. T.
Oza, A. M.
Korach, J.
Huzarski, T.
Pignata, S.
Colombo, N.
Park-Simon, T-W.
Tamura, K.
Sonke, G. S.
Freimund, A.
Lee, C. K.
Pujade-Lauraine, E.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S615 - S615
[7] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Gladieff, L.
Ferrero, A.
De Rauglaudre, G.
Brown, C.
Vasey, P.
Reinthaller, A.
Pujade-Lauraine, E.
Reed, N.
Lorusso, D.
Siena, S.
Helland, H.
Elit, L.
Mahner, S.
[J]. ANNALS OF ONCOLOGY, 2012, 23 (05) : 1185 - 1189
[8] An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer
Greimel, E
Bottomley, A
Cull, A
Waldenstrom, AC
Arraras, J
Chauvenet, L
Holzner, B
Kuljanic, K
Lebrec, J
D'haese, S
[J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (10) : 1402 - 1408
[9] CARBOPLATIN REINDUCTION AFTER TAXANE IN PATIENTS WITH PLATINUM-REFRACTORY EPITHELIAL OVARIAN-CANCER
KAVANAGH, J
TRESUKOSOL, D
EDWARDS, C
FREEDMAN, R
DELEON, CG
FISHMAN, A
MANTE, R
HORD, M
KUDELKA, A
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) : 1584 - 1588
[10] Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
Lorusso, D.
Scambia, G.
Pignata, S.
Sorio, R.
Amadio, G.
Lepori, S.
Mosconi, A.
Pisano, C.
Mangili, G.
Maltese, G.
Sabbatini, R.
Artioli, G.
Gamucci, T.
Di Napoli, M.
Capoluongo, E.
Ludovini, V.
Raspagliesi, F.
Ferrandina, G.
[J]. ANNALS OF ONCOLOGY, 2016, 27 (03) : 487 - 493

← 1 2 3 →